doi: https://doi.org/10.1101/2020.10.28.20221143
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
The Zimbabwe National Pharmacovigilance Policy Handbook, 2nd Edition updates the November 2013 version to indicate the Zimbabwe National Pharmacovigilance (PV) Centre’s compliance with the WHO Pharmacovigilance Indicators Handbook 2015.
20 February 2013
Update on 2004 Background Paper (Written by Saloni Tanna)
Priority Medicines for Europe and the World "A Public Health Approach to Innovation"
Se sabe desde hace tiempo que las mujeres con el VIH presentan un mayor riesgo de desarrollar cáncer cervicouterino; sin embargo, existen pocos datos e información sobre esta afección en la Región de las Américas. Este estudio, realizado entre el 2019 y el 2020, intenta brindar información y d...atos que puedan acelerar la aplicación de políticas de salud que atiendan la particular situación de las mujeres con el VIH respecto al cáncer cervicouterino.
more
Women and children, especially pregnant girls and women, infants and young children and postpartum women, are populations that are extremely vulnerable in emergencies. Breastfeeding provides children with hydration, comfort, connection, high quality nutrition and protection against disease, shieldin...g them from the worst of emergency conditions. This ability has been described as empowering and healing by some breastfeeding women.
more
Experience of national TB partnerships
National HIV curriculum
You can always find the most up to date version of this document at
https://www.hiv.uw.edu/go/co-occurring-conditions/opportunistic-infections-prevention/coreconcept/all
World Drug Report 2017
-1-
Accessed: 14.03.2019
These guidelines provide updated evidence-based recommendations on the priority HCV-related topics from the 2018 WHO Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C infection and the 2017 WHO Guidelines on hepatitis B and C testing. These priority areas are:
... direct-acting antiviral (DAA) treatment of adolescents and children ages ≥3 years of age
simplified HCV service delivery (decentralization, integration and task sharing)
HCV diagnostics – use of point-of-care (POC) HCV ribonucleic acid (RNA) assays and reflex HCV RNA testing.
These guidelines also update existing chapters without new recommendations, such as the inclusion of new manufacturers’ protocols on the use of dried blood spot (DBS) for HCV RNA testing and new data to inform the limit of detection for HCV RNA assays as a test of cure, in addition to their use for diagnosis.
more
Framework for implementation.
The END TB Strategy.